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Background: The clinical phenotype of Pseudoxanthoma elasticum (PXE) affected patients, although progressive
with age, is very heterogeneous, even in the presence of identical ABCC6 mutations, thus suggesting the occur-
rence of modifier genes. Beside typical skin manifestations, the cardiovascular (CV) system, and especially the
peripheral vasculature, is frequently and prematurely compromised.
Methods and results: A cohort of 119 Italian PXE patients has been characterized for apolipoprotein E (APOE)
andmethylenetetrahydrofolate reductase (MTHFR) gene polymorphisms by PCR. The severity of the clinical phe-
notype has been quantified according to the Phenodex PXE International score system. Statistical analysis (chi2
test, odd ratio, regression analysis, analysis of variance) were done by GraphPad. Data demonstrate that the fre-
quency of APOE alleles is similar in PXE patients and in healthy subjects and that the allelic variant E2 confers a
protection against the age-related increase of CV manifestations. By contrast, PXE patients are characterized by
high frequency of theMTHFR-T677T polymorphism.With age, CVmanifestations in T677T, but also in C677T, pa-
tients are more severe than those associated with the C677C genotype. Interestingly, compound heterozygosity
for C677T and A1298C polymorphisms is present in 70% of PXE patients.
Conclusions: PXE patients may be screened for these polymorphisms in order to support clinicians for a better
management of disease-associated CV complications.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Vascular calcification is a relevant clinical complication associated
with aging, atherosclerosis, hypertension, chronic kidney disease and
diabetes, being also correlated with increased risk of myocardial infarc-
tion. Furthermore, ectopic calcification occurs in a number of genetic
diseases as in Pseudoxanthoma elasticum (PXE), a rare autosomal re-
cessive disorder characterized by progressive mineralization of elastic
fibers within soft connective tissues [1], mainly affecting skin, vascular
walls and eyes [2]. In PXE, vessel alterations primarily consist ofmineral
plaques accumulating inside elastic fibers of medium sized arteries and
veins. Therefore, the most common cardiovascular complications are:
diminished or absent peripheral vascular pulses, mitral valve prolapse,
arterial hypertension, angina pectoris, early intermittent claudication
(often regarded as the first sign of accelerated atherosclerosis),r;Hcy, homocysteine;HDL, high
ductase; PXE, Pseudoxanthoma
pi 287, 41125 Modena, Italy.
lino).
. This is an open access article underarteriosclerosis and increased risk of myocardial and cerebral infarction
[2–5]. The age-dependent progression and severity of pathologicmanifes-
tations are very heterogeneous, thus suggesting that, beside ABCC6 caus-
ative mutations [6–8], other genes and/or polymorphisms contribute to
the clinical phenotype [9–12].
In addition to changes in the expression of molecules closely as-
sociated with the calcification process [13,14], PXE subjects suffer
from a condition of mild chronic oxidative stress [15–17]. It is well
known that altered redox balance contributes to atherosclerosis and
to vascular calcification and that several polymorphisms, as those in
the apolipoprotein E (APOE) and 5,10methylenetetrahydrofolate reduc-
tase (MTHFR) genes, are related to oxidative stress and to the develop-
ment of cardiovascular complications [18].
In particular, APOE polymorphisms are associated with many
diseases and it has been demonstrated that E2, E3 and E4 isoforms, hav-
ing a different structure, exhibit a modified susceptibility to oxidation
[19]. Consequently, APOE–protein interactions can be modified as well
as protein function. APOE is one of the major lipid acceptor, removing
cholesterol from cells and generating high density lipoprotein (HDL)
particles in an isoform-dependent manner [20]. The increased risk of
cardiovascular complications has been associated for instance to higherthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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APOE isoforms, possibly depending on the number of free available –SH
groups, have a different antioxidant activity (APOE2 N APOE3 N APOE4)
[22,23].
Another factor significantly contributing to oxidative damage in
vascular-related diseases is homocysteine (Hcy), a non-protein amino
acid capable of reacting specifically, and often quantitatively, with a
number of thiol-combining groups, many of which are present in pro-
teins and in other importantmolecules. Irreversible homocysteinylation
of long-lived proteins lead to cumulative damages and to oxidative
stress [24]. Hyperhomocysteinemia can be associated to MTHFR gene
polymorphisms or to vitamin B6, B12 or folic acid deficiency and
has been involved in the pathophysiology of cancer [25–27], cardio-
cerebrovascular diseases, atherosclerosis [28,29], renal failure [30] and di-
abetic retinopathy [31]. The MTHFR C677T polymorphism (rs1801133)
has been extensively investigated and the corresponding amino acid sub-
stitution results in a 30% to 60% decrease of the enzyme activity in hetero-
zygotes and homozygotes, respectively [32]. A second commonmutation
within the MTHFR gene, A1298C (rs1801131), results in significantly
reduced enzyme catalytic activity, even though only few studies have
focused on this polymorphism [33,34]. It has been also suggested that
the two polymorphisms (i.e. compound heterozygosity for C677T and
A1298C) presumably act in an additivemanner increasing the risk, for ex-
ample, for ischemic stroke [35].
In the present study Italian PXE patients have been investigated:
1) for the frequency of APOE allelic variants and of MTHFR C677T poly-
morphism in order to evaluate if they are randomly present in patients
or if there is an association with the disease; 2) to see if the severity of
cardiovascular manifestations are influenced by these polymorphisms,
thus representing additive genetic risk factors that could be counteracted
by appropriate life-style.2. Materials and methods
2.1. Patient's clinical data
Analyses were performed on 119 Pseudoxanthoma elasticum (PXE)
affected patients and on 103 healthy volunteers. Since PXE is more
frequently observed in females than in males [2], we have maintained
a female:male ratio of 2:1 within each group.
All subjects were of Italian origin and gave informed signed con-
sent in accordance with the guidelines of the Institutional Medical
Ethical Committee and of the Helsinki Declaration of 1975 revised
in 1983.
Clinical diagnosis of PXE was confirmed by the presence of calcified
elastic fibers on skin biopsies and on the identification of ABCC6 causa-
tive mutations (Supplemental Table 1) detected by already described
methods [36]. Age-matched healthy individuals were selected on the
basis of the absence of clinically evident pathologic conditions and of
cardiovascular complications.
The severity of the pathological phenotype, as documented by clini-
cal examinations, has been quantified according to the Phenodex score
that represents, nowadays, the only published standardized system
quantifying PXE clinical manifestations [37].
In particular, for the vascular system, V1was given toweak or absent
pulses, V2 to intermittent claudication and V3 to vascular occlusion or
other symptoms severe enough to require surgery. For cardiac symp-
toms, C1 denoted ischemic changes and angina, and C2 myocardial in-
farction. The cardiovascular score (CV) used in the present study was
the sum of V + C.
Cholesterol, high density lipoproteins (HDL), low density lipopro-
teins (LDL), triglycerides and homocysteine were measured in PXE pa-
tients by chemical analyses in certified laboratories under the control
of the Local Sanitary Units. Patients under statin therapy were analyzed
for polymorphisms, but their laboratory tests were not considered.2.2. Identification of APOE polymorphisms
Genomic DNA was isolated from whole blood (QIAamp blood kit,
Qiagen GmbH, Hilden, Germany), according to the manufacturer's in-
structions and stored at −80 °C until use.
Samples underwent the polymerase chain reaction (PCR) protocol
described by Hixson and Vernier [38]. Briefly, DNA was amplified
using oligonucleotide forward primer (5’-ACAGAATTCGCCCCGGCCTG
GTACACAC-3’) and reverse primer (5’-TAAGCTTGGCACGGCTGTCCAA
GGA-3’) (MWG-Biotech, Ebersberg, Germany) [39].
In a total volume of 30 μl, each amplification reaction contained
0.3 μg of genomic DNA from each patient, 3 μl of PCR Buffer 10x
(20 mM Tris–HCl pH 7.5, 100 mM KCl, 15 mM MgCl2, 1 mM DTT,
0.1 mM EDTA, 0.5% Tween 20, 0.5% Nonidet P40, 50% glycerol) (Roche,
Milan, Italy), 3 μl of each primer (MWG-Biotech), 0.6 μl of dNTPs mix
(10 mM of dATP, dCTP, dGTP, dTTP) (Fermentas, Milan, Italy), 3 μl
(10%) dimethyl sulfoxide (DMSO), 0.5 μl of High Fidelity Taq DNA poly-
merase corresponding to 1.73 U (Roche) plus sterile water. Samples
were heated at 94 °C for 5 min for denaturation, and subjected to 30 cy-
cles of amplification by primer annealing (6O°C for 1 min), extension
(70 °C for 2 min.) anddenaturation (95 °C for 1min) in a T3Thermocycler
(Biometra, Goettingen, Germany).
PCR amplification productswere evaluated by agarose gel electropho-
resis. Sampleswere digested by adding 1 μl of the restriction enzymeHhaI
(10 U/μl, Fermentas) for 3 h at 37 °C. Each reaction mixture was loaded
onto an agarose gel Metaphor (Cambrex Bio Science, Walkersville, USA)
4% in TAE 1× allowing to discriminate PCR products with small size vari-
ations. Electrophoresis was performed for 1 h and 30 min at 80 V. DNA
fragments were visualized by UV illumination and the size of HhaI frag-
ments was estimated by comparison with 0.1 μg of Gene Ruler 100 bp
DNA Ladder Plus (Fermentas).
2.3. Identification of MTHFR polymorphisms
Detection of C677T MTHFR polymorphism was performed by PCR
followed by HinfI restriction enzyme digestion. Briefly, we used the for-
ward primer 5′-CCT TGA ACA GGT GGA GGC CAG-3′ and the reverse
primer 5′-GCG GTG AGA GTG GGG TGG AG-3′ (Invitrogen, Monza,
Italy) to amplify a 294 base pair (bp) fragment of the MTHFR gene.
Each 25 μl PCR reaction contained 2.5 μl of 10x reaction buffer
(Roche), 1.5 mmol MgCl2 (Roche), 2 μl from 10 pmol of each primer,
0.2 mmol of the deoxynucleoside triphosphates, 1 U of Taq DNA poly-
merase (Roche), and 100 ng of genomic DNA template. The mixture
was denatured at 95 °C for 5 min, and the PCR reaction was performed
for 35 cycles in a thermocycler under the following conditions: denatur-
ation at 95 °C for 1 min, annealing at 65 °C for 30 s, and extension at
72 °C for 1 min. The final extension cycle of 72 °C was for 7 min. The
PCR products were electrophoresed on agarose gel (2%) to confirm the
correct amplicon size. Restriction enzyme digestion was performed on
PCR products using the HinfI restriction enzyme (Fermentas) following
the supplier's protocol. After digestion, all fragments were resolved on a
metaphor agarose gel (5%) (BIOSPA, Milan, Italy). A single fragment of
294 bp and two fragments of 168 and 126 bp identified the homozygous
(CC) and (TT) genotype, respectively, whereas three fragments of 294,
168, and 126 bp were indicative of the heterozygous (CT) condition.
The A1298C polymorphismwas detected by PCR in a total volume of
50 μl, containing: 5 μl of 10x reaction buffer (Roche), 10 pmol of the for-
ward primer 5′-CTT TGG GGA GCT GAA GGA CTA CTA C-3′ and 10 pmol
of the reverse primer 5′-CAC TTTGTGACCATTCCGGTT TG-3′, 10mMof
dNTP mix, 3.0 mM MgCl2 (Roche) and 1 unit Taq polymerase (Roche)
and 200 ng of genomic DNA. PCR parameters were as follows: an initial
denaturation step of 2 min at 92 °C, followed by 35 cycles of 92 °C for
60 s, 51 °C for 60 s, 72 °C for 30 s and a final extension for 7 min at
72 °C to ensure a complete extension of all PCR products. PCR products
were electrophoresed on an agarose gel (2%) to confirm the correct
amplicon size (163 bp). The sequence analysis of this PCR fragment
Table 2
Allele and genotype frequencies of the MTHFR (C677T) polymorphism in controls and in
PXE patients. The frequency of MTHFR T677T genotype was higher in PXE patients than





OR (95% CI) p valuea
Genotype
CC 34.0 24.3 1.00 (reference)
CT 48.5 48.0 1.417 (0.7335–2.736) 0.32
TT 17.5 27.7 2.333 (1.051–5.182) 0.04
Allele
C 58 48 1.00 (reference)
T 42 52 1.496 (0.8560–2.615) 0.16
a Fisher's test was used; p b 0.05was considered to be statistically significant (values in
bold).
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sion 2.1.2, Monza, Italy), using the ABI Prism Taq DyeDeoxy terminator
cycle sequencing ready reaction kit (Perkin Elmer, Waltham, USA), ac-
cording to the manufacturer's instructions.
2.4. Statistical analysis
GraphPad version 4.0 software was used for statistical analyses.
Differences between subgroupswere tested by ANOVA; categorical var-
iables were tested by χ2 analysis or by Fisher's exact test. Deviation of
genotype frequencies from those predicted by Hardy–Weinberg
law was tested by χ2 analysis. Odds ratios (OR) and 95% confidence in-
tervals (CI) were calculated to estimate the relative risk of the different
genotype combinations. Significance was set at p b 0.05.
3. Results and discussion
3.1. Frequency of APOE and MTHFR polymorphisms
All observed frequencies fittedwith those expected according to the
Hardy–Weinberg equilibrium.
The APOE genotype and the allele frequency distribution in PXE and
in healthy subjects are reported in Table 1. The frequencies in the con-
trol group were similar to those already reported for the general popu-
lation [40]. No significant differences between PXE and healthy subjects
were observed with regard to either genotype or allele frequencies. As
expected [41], the E3E3 genotypewas themost common in both groups,
E2E2 was absent in both controls and patients, whereas E4E4 was ab-
sent in patients, but present in 1.9% of healthy subjects and E2E4 was
present in 1.7% and 1% of patients and healthy subjects, respectively.
In contrast to APOE, several studies indicate that the frequency of the
homozygosity for the MTHFR-C677T polymorphism varies significantly
(from 1.4% to 15%) depending on the geographic area [42]. Consistently,
the risk of stroke associated with the T677T genotype is significantly el-
evated among the Japanese and the Italian population [28]. Therefore,
we have evaluated genotype and allele frequency of the C677T variant
in PXE patients and in control subjects (Table 2). Odds ratio indicates
that the relative frequencies of genotypes differ between PXE and con-
trol subjects (p b 0.05). In particular, in healthy controls, it was ob-
served that the frequency of CC and TT genotypes were 34.0% and
17.5%, respectively. To benoted is that thepercentage of control individ-
uals with the TT polymorphism is higher than that reported in popula-
tion from other countries [43], but in agreement with data from Sacchi
et al. [44]. In PXE, the CC and the TT genotypes account for 24.3% and
27.7% of patients, while 48% were heterozygous for the CT genotype.
Interestingly, thehomozygous genotypeMTHFR T677T had a higher fre-
quency in PXE patients (27.7%) than in controls (17.5%) (Table 2).Table 1
Allele and genotype frequencies of APOE polymorphisms in control and in PXE subjects.






OR (95% CI) p valuea
Genotype
E2E2 0 0
E3E3 63.1 74.1 1.00 (reference)
E4E4 1.9 0 0.1705 (0.008–3.619) 0.22
E2E3 12.6 10.3 0.6549 (0.2688–1.595) 0.37
E3E4 21.4 13.8 0.5676 (0.2667–1.208) 0.18
E2E4 1.0 1.7 1.703 (0.1507–19.23) 1.0
Allele
e2 7 6 0.7973 (0.2569–2.474) 0.78
e3 80 86 1.00 (reference)
e4 13 8 0.5725 (0.2254–1.454) 0.25
a Fisher's test was used; p b 0.05 was considered to be statistically significant.3.2. APOE polymorphisms and cardiovascular manifestations
Due to their low frequency, subjects with the ε2/ε4 genotype (1.7%)
were excluded andwere not considered in future analyses. PXE patients
were divided into three APOE subgroups: subjects carrying the ε2/ε3 ge-
notype (APOE2 group), the ε3/ε3 genotype (APOE3 group) and the ε3/ε4
genotype (APOE4 group). As expected [45], total cholesterol and low
density lipoprotein levels progressively increased with age in APOE3
and APOE4 patients, whereas changes were not significant in APOE2
subjects. Plasma triglyceride levels were not modified by age in any
APOE subgroups (Supplemental Fig. 1). Epidemiological data in the gen-
eral population have demonstrated that the APOE genotype is associat-
edwith increased risk of cardiovascular disease [46]. Therefore, we have
assessed if also in PXE APOE genotypehad an influence on the severity of
cardiovascular manifestations. Since in PXE CV complications usually
start at 30 years and then progresswith age, patients, divided according
to their APOE genotype, were further stratified into 3 age groups:
b30 years; 30–50 years and N50 years.
As shown in Fig. 1, PXE patients over the fifth decade andwithAPOE3
or APOE4 genotype had a CV score higher than those with the same ge-
notype in the lowest age group (b30 years). Moreover, in older patients
(N50 years) with the APOE4 genotype, CV complications were more se-
vere than those in APOE2 subjects. These results demonstrate that in
PXE, as well as in the general population [46], APOE2 confers protection
against age-related CV manifestations.3.3. MTHFR polymorphisms and cardiovascular manifestations
Similar analyses have been done for the MTHFR genotype (Fig. 2),
one of the factors that favor increased Hcy levels. Hcy can induce vascu-
lar injuries [47], extracellular matrix alterations [48] and connective tis-
sues structural remodeling [49]. Fig. 2 shows the CV score as a function
of bothMTHFR genotype and patients' age. The CV score increased with
age with significant differences in patients with C677T or T677T geno-
type. Consistently, PXE patients with the C677C genotype did not exhib-
it a significant age-dependent increase of the CV score, whereas PXE
subjects with C677T or T677T polymorphism presented, after 30 years
of age, a continuous progression in the severity of CV manifestations.
In order to better understand why the CV score was similarly affected
in the CT heterozygous and in the TT homozygous condition, we have
investigated the occurrence of polymorphism A1298C in patients het-
erozygous for C677T. It has in fact been demonstrated that the A1298C
polymorphism can affect MTHFR activity and Hcy concentration [51],
especially if combined with the C677T variant, thus leading to a condi-
tion similar to that observed in patients carrying the T677T genotype.
Interestingly, 70% of PXE patients was compound heterozygous for
bothMTHFR polymorphisms (C677T and A1298C), thus behaving simi-
larly to patients with the T677T polymorphism.
Fig. 1. The cardiovascular score (CV) in PXE patients according to the APOE genotype (APOE2: E2E3; APOE3: E3E3 and APOE4: E3E4). Patients were divided into three age subgroups (be-
fore 30 years of age, between the age of 30 and 50 years, after the age of 50 years). Significant p values are indicated in the right panel as stars. *p b 0.05; **p b 0.01.
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equate supply of folate, vitamin B12or vitamin B6 lead to elevated levels
of Hcy. Laboratory tests indicate that, in PXE patients, there is also a
graded increase in plasma Hcy concentrations from the CC to TT
genotypes of MTHFR–C677T polymorphism (CC = 9.4 mg/dl; CT =
15.5 mg/dl; TT= 21.2 mg/dl).Within this context, it is worthmention-
ing that in PXE patients high Hcy levels can be efficiently reverted to nor-
mal values by folate supplementation (e.g. 43.03 μmol/l at basal levels
were reduced to 8.57 μmol/l by vitamin B6 intake), thus demonstrating
that the disease does not affect patients' response to vitamin treatment.
However, since plasma Hcy levels are rapidly modified by diet and/
or vitamin supplementation, in terms of prognostic significance, genetic
analysis, being independent from these variables, represents the most
useful parameter to be investigated.
APOE and Hcy are risk factors for cardiovascular diseases and can in-
fluence each other's activities [50]. For instance, Hcy impairs APOE3
function by interfering with the dimerization of APOE3 and reducing
the APOE3-mediated HDL generation to a level similar to that of
APOE4, although it does not affect E4 isoform. Since PXE patients with
the APOE3 or the APOE4 genotype behave similarly, in contrast to
those with the APOE2 genotype, we have further analyzed patients
with the APOE3 or theAPOE4 genotype, dividing these subjects into sub-
groups on the basis of age and MTHFR–C677T polymorphism. Fig. 3
shows that the CV score, as expected, increased with age, however, de-
spite the lownumber of patients present in each group, the CV score sig-
nificantly increased in patients with C677T or T677T polymorphisms
over the fifth decade of life compared to younger patients. Therefore,
these data indicate that MTHFR polymorphisms can further modulate
the severity of cardiovascular manifestations in PXE patients.Fig. 2. The cardiovascular score (CV) in PXE patients according to theMTHFR genotype (CC: C
30 years of age, between the age of 30 and 50 years, after the age of 50 years). Significant p va4. Conclusion
Polymorphisms in the APOE and MTHFR genes are known to be
important risk factors for cardiovascular diseases. Since vascular
manifestations represent one of the most life-threatening complica-
tions in PXE patients, the identification of prognostic markers could
be of great importance.
Results from the present study demonstrate that: a) the frequency
of APOE polymorphisms is similar between patients and healthy sub-
jects, indicating the absence of a link between PXE and a specific APOE
genotype; b) as known for the general population, also in PXE patients,
the ε3 and ε4 alleles are associatedwith a similarly higher age-dependent
increase of cardiovascular manifestations compared to ε2 patients. More-
over, as far as the MTHFR gene it has been observed that: a) T677T
polymorphism has been found at a frequency higher in patients
than in controls; b) with age, PXE patients homozygous for the
C677C polymorphism do not exhibit a significant age-dependent in-
crease of the CV score as patients carrying C677T and T677T poly-
morphisms; c) compound heterozygosity for C677T and A1298C
polymorphisms is present in 70% of PXE patients; d) MTHFR poly-
morphisms influence the age-dependent increase of the CV score
in PXE patients further modulating the APOE genotype.
Although this study is limited to a number slightly over one hundred
of patients, it has to be underlined that, since PXE is a rare disease, this
represents a consistent cohort, that, most importantly, is of homoge-
neous geographical origin. Ethnic differences must therefore be consid-
ered when the frequency of specific mutations/polymorphisms is
evaluated in larger groups of patients. Data from this study suggest
thatMTHFR polymorphismsmay be playing a role in PXE cardiovascular677C; CT: C677T and TT: T677T). Patients were divided into three age subgroups (before
lues are indicated in the right panel as stars. *p b 0.05; **p b 0.01; ***p b 0.001.
Fig. 3. The cardiovascular score (CV) was evaluated in APOE3 and APOE4 PXE patients stratified according to MTHFR polymorphisms (CC: C677C; CT: C677T and TT: T677T) and age. In
particular, patients were divided into three age subgroups (before 30 years of age, between the age of 30 and 50 years and after the age of 50 years). Significant p values are indicated
in the right panel as stars. *p b 0.05; **p b 0.01; ***p b 0.001.
481F. Boraldi et al. / Molecular Genetics and Metabolism Reports 1 (2014) 477–482complications and, since Hcy levels can be controlled by appropriate vi-
tamin supplementation, PXE patients could be investigated for both
MHTFR polymorphisms in order to adopt appropriate diet regimens to
counteract the “at-risk” MTHFR genotype.
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